Jamieson Wellness Publishes Inaugural Sustainability Impact Report

From values to action, the Company details progress towards its sustainability commitments in its "Inspiring Better Lives Every Day: 2023 Sustainability Impact Report"

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today announces the release of its "Inspiring Better Lives Every Day: 2023 Sustainability Impact Report". The comprehensive report underscores the Company's commitment to creating a sustainable future while aligning with its core values of Respect, Excellence, Accountability, and Agility. The Company's new purpose, "Inspiring Better Lives Every Day," serves as its guiding light as it navigates the path toward positive impact.

Key Highlights from the 2023 report:

  • Performance Metrics: The report meticulously outlines the Company's performance across various dimensions, including promoting diversity in the workplace, fostering wellbeing within Jamieson Wellness and its communities, and progress towards climate and biodiversity targets
  • ‘Progress For Our People': Jamieson Wellness has embarked on several initiatives aimed at improving the wellbeing of its consumers, team members, and communities, from inclusion and equitable workplace training, to protecting human rights and supporting community giving programs
  • ‘Progress For Our Planet': Transparent insights into the Company's progress toward achieving ambitious sustainability goals, including a new environmental policy, as well as the introduction of Ocean-Friendly Omega, the youtheory brand's award-winning plant-based omega-3 product
  • ESG Scorecard: As part of the Company's commitment to its value of Accountability, the report presents its Environmental, Social, and Governance (ESG) Scorecard. This includes adherence to the new International Sustainability Standards Board's global standards, incorporating the Task Force on Climate-Related Financial Disclosures recommendations, and reporting its Sustainability Accounting Standards Board metrics
  • Greenhouse Gas Inventory Assurance Report: The Company's greenhouse gas emissions inventory is disclosed in this report for the first time. It undergoes rigorous assurance processes and will be reported annually as part of the Company's dedication to reaching Net Zero by 2050

"We are immensely proud of the progress we have made in our ESG initiatives, and of the dedicated work that went into creating this comprehensive report," said Mike Pilato, President and CEO of Jamieson Wellness. "This report not only reflects our unwavering commitment to a healthier world, but it also resonates deeply with our company purpose: "Inspiring Better Lives Every Day". As we continue to lead with purpose, innovate, and drive positive change, we invite our stakeholders to join us on this transformative journey."

The full report can be found on the Company's website here .

About Jamieson Wellness

Jamieson Wellness is dedicated to Inspiring Better Lives Every Day with its portfolio of innovative natural health brands. Established in 1922, the Jamieson brand is Canada's #1 vitamins, minerals and supplements ("VMS") brand. The Company's youtheory brand, acquired in 2022, is an established and growing lifestyle brand in the U.S. Combined, these global brands are available in more than 50 countries worldwide. The Company also offers a variety of innovative VMS products as well as sports nutrition products to consumers in Canada with its Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

Investor Relations and Media Contact Information:
Jamieson Wellness
Ruth Winker
416-960-0052
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...

Interactive Chart

Latest Press Releases

Related News